gemcitabine + panitumumab

**gemcitabine + panitumumab** is a combination regimen of the nucleoside analog cytotoxic chemotherapy agent gemcitabine and the fully human monoclonal antibody panitumumab, used experimentally in the treatment of advanced malignancies such as KRAS wild-type biliary tract cancer and pancreatic adenocarcinoma. - **Gemcitabine** is a small molecule antimetabolite that interferes with DNA synthesis by inhibiting DNA polymerase during the S-phase of the cell cycle, resulting in apoptosis and inhibition of tumor cell proliferation. - **Panitumumab** is an anti-EGFR (epidermal growth factor receptor) monoclonal antibody that binds to EGFR on tumor and normal cells, competitively inhibiting ligand binding, blocking receptor activation, promoting receptor internalization, and thereby inhibiting cell proliferation, survival, and angiogenesis in EGFR-expressing tumors. Both agents are administered intravenously. Several phase II studies have reported the efficacy and tolerability of this combination regimen (occasionally with additional agents) in KRAS wild-type biliary tract and pancreatic cancers, with encouraging disease control and manageable adverse events[5][9][4].